Navigation Links
WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting
Date:5/9/2008

of a five

year warrant to purchase up to 3,400,000 common shares of the

Company, exercisable at US$0.01 per share, issued to Abiomed in

connection with the secured promissory note.

The election of directors, the appointment of the auditors and the conversion of the note and exercise of the warrant issued to Abiomed were carried by a majority of the votes at the meeting in person or by proxy. A copy of the Voting Results, which includes the percentage outcome of the votes cast, is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product development and market acceptance of and demand for the Company's products; delisting from the NASDAQ Stock Market if compliance with the listing standards, including the Minimum Bid Price Rule and other minimum standards, is not regained; and other risks detailed in the Corporation's filings with the U.S. Securities and
'/>"/>

SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WorldHeart 10-KSB Audit Report Includes Going Concern Qualification
2. WorldHeart Schedules Teleconference
3. Cardium Reports on First Quarter 2008 Highlights and Financial Results
4. Novavax Reports First Quarter 2008 Financial Results
5. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
6. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... NEW BRUNSWICK, N.J. , March 30, 2015 /PRNewswire-USNewswire/ ... research and innovation projects in the state of ... to its next round of grant funding, announced ... existing New Jersey Health Foundation Research Grants program, an ... to $35,000 each to fund early stage research projects ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ... device company, today announced unaudited interim and ... and year ended,December 31, 2007. The unaudited ... potential adjustment as described under the section ...
... million to $360 million, WARSAW, Ind., Feb. 14 ... provider of products to the global orthopedic,device industry and ... of $79.1 million. The Company stated that,additional financial results ... previously announced on October 4, 2007, the Company,s Audit,Committee ...
... Experience in Biopharmaceutical Manufacturing, Engineering, Technical Services and ... ... 14 Laureate Pharma, Inc., a,full-service biopharmaceutical development and protein production ... In this newly created position, Mr. Swan will be responsible,for leading ...
Cached Biology Technology:Angiotech announces results for the fourth quarter ended December 31, 2007 2Angiotech announces results for the fourth quarter ended December 31, 2007 3Angiotech announces results for the fourth quarter ended December 31, 2007 4Angiotech announces results for the fourth quarter ended December 31, 2007 5Angiotech announces results for the fourth quarter ended December 31, 2007 6Angiotech announces results for the fourth quarter ended December 31, 2007 7Angiotech announces results for the fourth quarter ended December 31, 2007 8Angiotech announces results for the fourth quarter ended December 31, 2007 9Angiotech announces results for the fourth quarter ended December 31, 2007 10Angiotech announces results for the fourth quarter ended December 31, 2007 11Angiotech announces results for the fourth quarter ended December 31, 2007 12Angiotech announces results for the fourth quarter ended December 31, 2007 13Angiotech announces results for the fourth quarter ended December 31, 2007 14Angiotech announces results for the fourth quarter ended December 31, 2007 15Angiotech announces results for the fourth quarter ended December 31, 2007 16Angiotech announces results for the fourth quarter ended December 31, 2007 17Angiotech announces results for the fourth quarter ended December 31, 2007 18Angiotech announces results for the fourth quarter ended December 31, 2007 19Angiotech announces results for the fourth quarter ended December 31, 2007 20Angiotech announces results for the fourth quarter ended December 31, 2007 21Angiotech announces results for the fourth quarter ended December 31, 2007 22Angiotech announces results for the fourth quarter ended December 31, 2007 23Angiotech announces results for the fourth quarter ended December 31, 2007 24Symmetry Medical Reports Preliminary Fourth Quarter Revenue 2Symmetry Medical Reports Preliminary Fourth Quarter Revenue 3Symmetry Medical Reports Preliminary Fourth Quarter Revenue 4Laureate Pharma Appoints Gary Swan as Vice President of Operations 2
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)... Transforming How We Look at ... in Human Space Flight" by Michael A. ... Ph.D. was recently featured by Springer Science Media, highlighting the ... Specifically, "Personalized Medicine in Human Space Flight" was ... 2013 and 2014 from Springer in the journal ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... Case Western Reserve University have found a way to create ... the developing heart in an animal model a key ... begun testing the technology to uncover how alcohol, drugs and ... in newborn humans. Passing blood cells drag on ...
... to rice cultivation built in the middle basin of the ... various migratory dabbling duck species to significantly increase in number ... that Vegas Altas del Guadiana is turned into a new ... populations are in decline and the loss of natural wetland ...
... - People tend to think of ozone as something ... from UV radiation. At the ground level, however, ozone ... Lisa Ainsworth, a University of Illinois associate professor of ... biologist, said that establishing the exposure threshold for damage ...
Cached Biology News:Finding triggers of birth defects in an embryo heart 2Ducks flock to Extremadura thanks to its ricefields 2Ducks flock to Extremadura thanks to its ricefields 3Ozone's impact on soybean yield: Reducing future losses 2Ozone's impact on soybean yield: Reducing future losses 3
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Corticoliberin...
...
Biology Products: